CytomX Therapeutics Inc (CTMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has a cash flow conversion efficiency ratio of -0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.07 Million) by net assets ($302.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of CytomX Therapeutics Inc for the company's overall valuation and market capitalisation.
CytomX Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how CytomX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CytomX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytomX Therapeutics Inc ranked by their cash flow conversion efficiency. Explore CTMX operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SurModics Inc
NASDAQ:SRDX
|
0.013x |
|
India Tourism Development Corporation Limited
NSE:ITDC
|
0.014x |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
0.000x |
|
Svolder AB (publ)
ST:SVOL-B
|
0.002x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
|
Arvind Fashions Limited
NSE:ARVINDFASN
|
0.103x |
|
Wuxi Xuelang Environmental Technology Co Ltd
SHE:300385
|
0.201x |
|
Basellandschaftliche Kantonalbank
SW:BLKB
|
-0.315x |
Annual Cash Flow Conversion Efficiency for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of CytomX Therapeutics Inc from 2013 to 2025. View CytomX Therapeutics Inc (CTMX) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $99.01 Million | $-75.59 Million | -0.763x | -100.40% |
| 2024-12-31 | $-456.00K | $-86.23 Million | 189.103x | +15912.09% |
| 2023-12-31 | $-47.45 Million | $-56.03 Million | 1.181x | -8.59% |
| 2022-12-31 | $-85.75 Million | $-110.79 Million | 1.292x | +197.01% |
| 2021-12-31 | $89.38 Million | $-119.03 Million | -1.332x | -96.86% |
| 2020-12-31 | $-7.77 Million | $5.26 Million | -0.676x | +75.39% |
| 2019-12-31 | $51.11 Million | $-140.48 Million | -2.748x | -376.32% |
| 2018-12-31 | $130.88 Million | $-75.52 Million | -0.577x | -123.67% |
| 2017-12-31 | $69.90 Million | $170.37 Million | 2.438x | +9514.09% |
| 2016-12-31 | $78.48 Million | $-2.03 Million | -0.026x | +88.09% |
| 2015-12-31 | $126.07 Million | $-27.41 Million | -0.217x | +46.29% |
| 2014-12-31 | $-78.54 Million | $31.80 Million | -0.405x | -323.89% |
| 2013-12-31 | $-44.28 Million | $-8.01 Million | 0.181x | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more